ADCT ADC Therapeutics SAcompanySEC Filings & Insider Trading Activity 2026
Latest ADC Therapeutics SA (ADCT) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on March 10, 2026, a 10-Q quarterly report filed on November 10, 2025, an 8-K current report filed on March 10, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for ADC Therapeutics SA (ADCT) (SEC CIK 1771910), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 8-K Current Report AnalysisRecent 8-K Filings
Item 2.02: Results of Operations and Financial Condition
- • Q4 and full-year 2025 earnings released March 10, 2026; full results in Exhibit 99.1
- • ADCT is a clinical-stage antibody-drug conjugate company — revenue and cash runway figures in the press release are key investor metrics to review
Item 1.01: Entry into a Material Definitive Agreement
- • HCR royalty deal amended: change-of-control payment slashed from up to $750M to $150M (before 2028) or $200M (after 2028)
- • Post-acquisition royalty obligations can be bought out for $525M (by end 2029) or $750M (by end 2030), less prior royalties paid and CoC payment
Item 3.02: Unregistered Sales of Equity Securities
- • Warrants issued to HCR for 9,834,776 common shares at $3.8130/share, exercisable through Dec 31, 2030
- • Lock-up on warrant transfers and underlying shares until Dec 31, 2027 — limits near-term selling pressure but caps HCR's flexibility
Recent 8-K FilingsCurrent Reports
AI-powered analysis of ADC Therapeutics SA (ADCT) 8-K current reports disclosing material events.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Mar 10, 2026 | — | Analysis | — |
10-K | Mar 10, 2026 | Dec 31, 2025 | — | |
8-K | Feb 23, 2026 | — | Analysis | — |
8-K | Jan 12, 2026 | — | — | |
8-K | Jan 8, 2026 | — | — | |
8-K | Dec 5, 2025 | — | — | |
10-Q | Nov 10, 2025 | Sep 30, 2025 | — | |
10-Q | Aug 12, 2025 | Jun 30, 2025 | — | |
10-Q | May 14, 2025 | Mar 31, 2025 | — | |
10-K | Mar 27, 2025 | Dec 31, 2024 | — | |
10-Q | Nov 7, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 6, 2024 | Jun 30, 2024 | — | |
10-Q | May 6, 2024 | Mar 31, 2024 | — | |
10-K | Mar 13, 2024 | Dec 31, 2023 | — | |
20-F | Mar 15, 2023 | Dec 31, 2022 | — | |
20-F | Mar 17, 2022 | Dec 31, 2021 | — | |
20-F | Mar 18, 2021 | Dec 31, 2020 | — |
Frequently Asked Questions
What are the latest ADCT SEC filings in 2026?
ADC Therapeutics SA (ADCT) has filed a 10-K annual report on March 10, 2026, a 10-Q quarterly report on November 10, 2025, an 8-K current report on March 10, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did ADCT file its most recent 10-K annual report?
ADC Therapeutics SA (ADCT) filed its most recent 10-K annual report on March 10, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view ADCT 10-Q quarterly reports?
ADC Therapeutics SA (ADCT)'s most recent 10-Q quarterly report was filed on November 10, 2025. SignalX displays every ADCT 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has ADCT filed recently?
ADC Therapeutics SA (ADCT)'s most recent 8-K was filed on March 10, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find ADCT insider trading activity (Form 4)?
SignalX aggregates every ADCT Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does ADCT file with the SEC?
ADC Therapeutics SA (ADCT) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new ADCT filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for ADC Therapeutics SA (ADCT).
What is ADCT's SEC CIK number?
ADC Therapeutics SA (ADCT)'s SEC CIK (Central Index Key) number is 1771910. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1771910 to look up all ADCT filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find ADCT return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from ADC Therapeutics SA (ADCT) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of ADC Therapeutics SA SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 17+ filings.